Too Old to Operate13h
Adjuvant Durvalumab Does Not Improve Survival in Completely Resected NSCLC
Adjuvant durvalumab did not improve disease-free survival in patients with early-stage non-small cell lung cancer in the phase 3 BR.31 trial.
Renal & Urology News1d
Will Durvalumab Transform Standard Care in MIBC?
Source: Getty Images Perioperative durvalumab has “the potential to transform the standard of care” for patients with ...
Targeted Oncology1d
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC
NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
Targeted Oncology2d
Adjuvant/Neoadjuvant Therapies Are Addressed in Lung Cancer
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
Nektar presents late-breaking results from Phase 2 Study of NKTR-255
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
NPPA asks companies to cut prices of three cancer drugs post tax relief
In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...